

# Deformable and degradable nanozymes for inhaled viral pneumonia treatment

Junfeng Song, Tiancong Zhao\*

The persistent threat of viral pneumonia to global health highlights the ongoing challenge facing the treatment for this infectious disease.<sup>1</sup> Conventional therapeutic strategies, including the use of antiviral drugs and supportive care, have demonstrated their limitations, especially against newly emerging viral strains. The time-consuming nature of developing vaccines for these variants restricts prompt responses to outbreaks. Therefore, there is an urgent need to establish a broad-spectrum treatment strategy for viral pneumonia.<sup>2</sup>

Viral pneumonia, frequently caused by viruses such as Influenza A (Flu A) or Sendai virus (SeV), is marked by an overactive inflammatory response and elevated levels of reactive oxygen species (ROS) within the lung tissues. This oxidative stress not only intensifies inflammation but also leads to tissue damage and compromised immune function. While natural enzymes play a crucial role in maintaining the redox balance in living organisms, they are prone to losing their activity under pathological conditions, leading to the secretion of nanozymes.<sup>3,4</sup> However, accurately delivering and concentrating nanozymes at the site of inflammation to treat viral pneumonia presents a significant challenge due to the complexity of internal inflammation.

In a recent work published in *Nature Materials*, Peng *et al.*<sup>5</sup> reported the development of an innovative nasal inhalable platform, CeTA-K<sub>1</sub>tkP, for the treatment of viral pneumonia. This platform combines a degradable cerium-based tannic acid nanozyme with a self-assembling peptide (Figure 1A-C). In areas of inflammation with high ROS levels, CeTA-K<sub>1</sub>tkP triggers the release of polyethylene glycol and forms a fibrous structure, effectively scavenging ROS and alleviating inflammation without systemic immune suppression. Notably, CeTA-K<sub>1</sub>tkP demonstrated the ability to bind viral proteins, potentially neutralizing the virus and mitigating bacterial inflammation in pneumonia models. This nanoplateform offers a promising approach for managing severe inflammations such as pneumonia.

The CeTA nanozymes are synthesized from tannic acid and cerium nitrate, showing enhanced

catalase-like and superoxide dismutase-like activities at higher concentrations. The CeTA-K<sub>1</sub>tkP nanoplateform, integrating CeTA with a self-assembling peptide, exhibits reactive self-assembly in ROS-rich environments, forming  $\beta$ -sheet structures that boost its catalytic and ROS-scavenging capabilities. This nanoplateform also exhibits targeted accumulation in inflamed regions, effectively reducing ROS and inflammation, highlighting its potential for precise therapy in the treatment of inflammatory diseases.

The CeTA-K<sub>1</sub>tkP nanoplateform has demonstrated potential in treating viral pneumonia by improving the over-oxidative environment. In a mouse model of H1N1-induced pneumonia, CeTA-K<sub>1</sub>tkP inhalation therapy showed broad-spectrum therapeutic effects, reducing inflammation and viral load and restoring normal alveolar morphology. The treatment led to a significant decrease in inflammatory cytokines such as interleukin (IL)-6, tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), and IL-1 $\beta$  in bronchoalveolar lavage fluid and serum. *In vitro* experiments confirmed CeTA-K<sub>1</sub>tkP's neutralizing effect on the Flu A virus, with binding to the HA protein of H1N1 viruses. Molecular docking suggested that tannic acid in CeTA-K<sub>1</sub>tkP interacts with HA proteins, forming hydrogen bonds and hydrophobic interactions. In a pulmonary virus infection model using SeV, CeTA-K<sub>1</sub>tkP nasal administration attenuated inflammation and regulated the production of inflammatory cytokines (Figure 1D). The treatment increased the expression of the antioxidant gene *HO-1* and decreased the pro-oxidant gene *Nox2*, suggesting a rebalancing of redox homeostasis. CeTA-K<sub>1</sub>tkP also reduced SeV viral load and showed neutralization ability *in vitro*. The treatment promoted the conversion of macrophages from pro-inflammatory M1 to anti-inflammatory M2 phenotypes, indicating the potential to inhibit viral-infection-related immunological disorders and lung damage. CeTA-K<sub>1</sub>tkP also showed therapeutic efficacy in a model of viral pneumonia combined with

Department of Chemistry, School of Chemistry and Materials, Laboratory of Advanced Materials and Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai, China

\*Corresponding author:


Tiancong Zhao,  
tczhao@fudan.edu.cn

<http://doi.org/10.12336/biomatertransl.2025.01.008>

How to cite this article:

Song, J.; Zhao, T. Deformable and degradable nanozymes for inhaled viral pneumonia treatment. *Biomater Transl.* 2025, 6(1), 103-105.





**Figure 1.** (A) Schematic presentation of the enzyme-like activities of CeTA nanozyme. (B) Schematic illustration of the self-assembly performance of the CeTA-K1tkP nanoplatform. Created with Biorender.com.

bacterial infection. The treatment minimized secondary bacterial lung damage, reduced the expression of inflammatory cytokines, and effectively regulated macrophage polarization in the inflammatory environment.

In summary, this work has developed a novel degradable and safe inhalable CeTA nanozyme based on peptide-based biological self-assembly for the treatment of viral pneumonia. Building upon the design that enables the material to respond to the deformation of the inflammatory microenvironment, this work also provides a detailed characterization of the material's ability to alleviate the microenvironment of viral pneumonia. It is an excellent work that balances the dual innovation of material design and preparation with biomedical effects, opening up new directions for smart biomaterials. Inhalable formulations have always been of great interest due to their simple administration methods and specific targeting pathways.<sup>6,7</sup> However, due to the fragile environment of the lungs and the weak metabolic capacity, the development of

nanomaterials, especially inorganic materials, in the field of inhalable formulations has not been entirely satisfactory.<sup>8</sup> The degradable nanoenzymes developed in this work have also been thoroughly validated for their biosafety and *in vivo* metabolic pathways, potentially paving the way for a new direction in inhalable bio-nanomaterials.

**Author contributions**

Conceptualization: TZ; Writing – original draft: JS; Writing – review & editing: TZ. All authors read and approved the final manuscript.

**Financial support**

The work was supported by the National Natural Science Foundation of China (22305042, 22475048).

**Acknowledgement**

None.

**Conflicts of interest statement**

The authors declare no conflicts of interest.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Availability of data**

Not applicable.

**Open access statement**

This is an open-access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**References**

1. Ruuskanen O, Lahti E, Jennings L, Murdoch D. Viral pneumonia. *Lancet*. 2011;377:1264-1275. doi: 10.1016/S0140-6736(10)61459-6
2. Vigant F, Santos N, Lee B. Broad-spectrum antivirals against viral fusion. *Nat Rev Microbiol*. 2015;13:426-437. doi: 10.1038/nrmicro3475
3. Jiang D, Ni D, Rosenkrans Z, Huang P, Yan X, Cai W. Nanozyme: New horizons for responsive biomedical applications. *Chem Soc Rev*. 2019;48:3683-3704.
4. Wang H, Wan K, Shi X. Recent advances in nanozyme research. *Adv Mater*. 2019;31:e1805368. doi: 10.1002/adma.201805368
5. Peng W, Tai W, Li B, et al. Inhalable nanocatalytic therapeutics for viral pneumonia. *Nat Mater*. 2024. doi: 10.1038/s41563-024-02041-5
6. Bai X, Chen Q, Li F, et al. Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy. *Nat Commun*. 2024;15:6844. doi: 10.1038/s41467-024-51056-8
7. Ye T, Jiao Z, Li X, et al. Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. *Nature*. 2023;624:630-638. doi: 10.1038/s41586-023-06809-8
8. Li J, Wu S, Guo X, et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: A randomised, open-label, single-centre trial. *Lancet Respir Med*. 2022;10:739-748. doi: 10.1016/S2213-2600(22)00087-X

Received: January 22, 2025

Revised: March 10, 2025

Accepted: March 13, 2025

Available online: March 25, 2025